ISPC iSpecimen Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1558569 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-92.1%
TTM net income YoY-12.0%
TTM EPS YoY173.0%
Revenue 3-yr CAGR-64.1%
Net income 3-yr CAGR—
Margins
Gross margin-98.0%
Operating margin-2,020.0%
Net margin-2,449.0%
FCF margin—
EBITDA margin-1,899.3%
Returns
ROE-968.5%
ROA-170.1%
ROIC (approx.)—
Asset turnover0.07x
Leverage & solvency
Liabilities / assets76.5%
Debt / equity0.00x
Current ratio0.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.61x
Accruals ratio-65.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.93M | $9.29M | $9.93M | $10.40M | $11.14M |
| Cost of revenue | $1.71M | $5.11M | $4.77M | $4.76M | $5.25M |
| Gross profit | $215,665 | $4.18M | $5.16M | $5.65M | $5.89M |
| R&D expense | — | $1.49M | $1.62M | $1.47M | $879,243 |
| SG&A expense | $3.47M | $6.07M | $5.94M | $6.93M | $5.61M |
| Operating income | -$8.98M | -$12.73M | -$11.17M | -$10.19M | -$5.93M |
| Interest expense | $1,949 | $173,771 | $16,001 | $238,963 | $2.10M |
| Income tax | — | — | — | $0 | $0 |
| Net income | -$10.49M | -$12.50M | -$11.10M | -$10.25M | -$8.96M |
| EBITDA | -$7.25M | -$10.43M | -$9.05M | -$10.16M | -$5.88M |
| EPS (basic) | -2.28 | -17.58 | -24.55 | -1.16 | -2.09 |
| EPS (diluted) | -2.28 | -17.58 | -24.55 | -1.16 | -2.09 |
| Weighted avg. shares (diluted) | 4.60M | 710,852 | 452,067 | 8.84M | 4.29M |
| Balance sheet | |||||
| Cash & equivalents | $6.88M | $1.88M | $2.34M | $15.31M | $27.74M |
| Short-term investments | — | — | $2.66M | $0 | — |
| Receivables | $48,298 | $1.44M | $728,388 | $1.60M | $3.00M |
| Inventory | — | $45,110 | — | — | — |
| Current assets | $6.95M | $3.59M | $8.24M | $19.68M | $32.95M |
| PP&E, net | $25,543 | $93,563 | $127,787 | $225,852 | $32,781 |
| Total assets | $9.53M | $9.35M | $15.82M | $24.62M | $35.72M |
| Current liabilities | $6.23M | $5.77M | $6.05M | $4.28M | $2.51M |
| Long-term debt | — | — | — | — | $3.42M |
| Total debt | — | — | — | — | $3.42M |
| Total liabilities | $6.44M | $6.04M | $6.08M | $4.31M | $5.93M |
| Shareholders' equity | $3.09M | $3.31M | $9.74M | $20.31M | $29.79M |
| Net debt | — | — | — | — | -$24.32M |
| Shares outstanding | 211,976 | 1.70M | 454,169 | 8.93M | 8.73M |
| Cash flow statement | |||||
| Operating cash flow | -$4.24M | -$8.26M | -$5.81M | -$5.82M | -$10.67M |
| Capital expenditure | $454 | $31,546 | $19,478 | $215,504 | $2,550 |
| Free cash flow | -$4.24M | -$8.30M | -$5.83M | -$6.03M | -$10.67M |
| Investing cash flow | -$1.00M | $1.98M | -$7.23M | -$3.19M | -$1.04M |
| Financing cash flow | $10.24M | $5.82M | $70,889 | -$3.42M | $38.75M |
| Depreciation & amortization | $1.73M | $2.29M | $2.12M | $22,433 | $45,358 |
| Stock-based compensation | $21,266 | $249,675 | $459,666 | $678,613 | $622,064 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.